Inspira Technologies announced that NYU Langone Health issued a $580,000 commercial purchase order for the company’s FDA-cleared ART100 extracorporeal blood circulation systems following a multi-patient hospital evaluation.
The order was placed through Inspira’s U.S. distributor after NYU Langone completed a clinical evaluation involving more than 30 patients across a range of cardiopulmonary and surgical cases. According to the company, the systems are scheduled for immediate fulfillment.
Inspira said the evaluation enabled NYU Langone to integrate the ART100 platform into hospital workflows and assess the system’s operational capabilities before moving forward with commercial procurement. The company added that the order comes as it continues discussions with additional U.S. and international hospital systems evaluating extracorporeal support technologies.
The ART100 is an FDA-cleared extracorporeal blood circulation system designed for use in cardiopulmonary bypass procedures. Inspira noted that the platform is currently under evaluation at additional U.S. hospitals and remains part of the company’s active strategic process involving potential transactions tied to the ART100 system and other medical assets.
NYU Langone Hospital is part of NYU Langone Health, which was named to the 2025–2026 U.S. News & World Report “Best Hospitals” Honor Roll and ranked No. 1 nationally in several specialties including cardiology, heart and vascular surgery, pulmonology and lung surgery, neurology and neurosurgery, and geriatrics.
Inspira Technologies continues to advance medical technology platforms focused on respiratory support and blood monitoring while also expanding its electronics manufacturing and quantum connectivity initiatives following its acquisition of an Additively Manufactured Electronics platform.
KEY QUOTES:
“NYU Langone’s transition from hospital-based evaluation to commercial purchase reflects the operational value of the ART100 platform in real hospital use. This order provides an important hospital reference as we continue commercial discussions with additional U.S. and international hospital systems evaluating extracorporeal support technologies.”
Mike Hershkovitz, VP of Global Sales, Inspira Technologies
“Our search for the future of extracorporeal support through innovation and cost-effective technology led us to Inspira. The ART100 demonstrated the type of flexibility, usability, and economic potential we believe will be important for the future of extracorporeal support.”
Fred Hill, Director of Extracorporeal Technology, NYU Langone Hospital
